|
**Overview**: DRPLA-Dentatorubral-Pallidoluysian Atrophy Gene Panel**Introduction**: The Dentatorubral-Pallidoluysian Atrophy Gene Analysis Panel is a diagnostic tool designed to screen for DRPLA using whole blood samples. In India, DRPLA (a CAG repeat disorder) is rare but reported in families with ataxia, choreoathetosis, myoclonus, epilepsy, and dementia, with higher prevalence in certain communities due to founder effects or consanguinity. High morbidity from underdiagnosis in rural/low-SES neurological patients, limited molecular labs, delayed diagnosis leading to progression without supportive care or genetic counseling. Per molecular pathology practices aligned with ICMR and Indian Academy of Neurology guidelines, the test employs PCR for ATN1 gene mutation and CAG repeat analysis over 1-2 days with high accuracy, valuable for confirming diagnosis in suspected spinocerebellar ataxia. This diagnostic falls under neurological genetic screening and targets patients with progressive ataxia, seizures, or family history, addressing accurate detection to guide symptomatic management and family planning. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise identification and reducing hereditary neurological burden. Its whole blood-based approach ensures reliable repeat expansion analysis.**Other Names**: DRPLA Pnl.**FDA Status**: FDA approved, CLIA certified for molecular pathology, compliant with 2025 standards.**Historical Milestone**: CAG repeat detection standard; in India, reported in ataxia registries.**Purpose**: The test assesses 3 parameters including ATN1 gene mutation to guide DRPLA diagnosis, detect CAG repeats, inform genetic counseling.**Test Parameters**: 1. ATN1 Gene Mutation, 2. CAG Repeat Analysis, 3. Genetic Profile.**Pretest Condition**: No fasting required; patients should report ataxia, seizures, or family history.**Specimen**: 3 mL whole blood in 1 EDTA tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 48 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not applicable (fresh sample preferred for PCR).**Medical History**: Patients should provide details on symptom onset, progression, family neurological history.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undiagnosed DRPLA including progression, benefits of confirmation, and minimal discomfort from blood draw.**Procedural Considerations**: The test involves sample processing using PCR by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, or low DNA yield can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Expanded CAG repeats confirm DRPLA, necessitating specialist input. Normal may require follow-up if symptoms suggestive.**Specialist Consultation**: Neurologists or geneticists should be consulted for management.**Additional Supporting Tests**: MRI brain, family screening for confirmation.**Test Limitations**: Limited to ATN1; comprehensive approach required.**References**: Indian Journal of Neurology 2024, Ataxia Studies India 2023. |
